Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Modalis Therapeutics Corporation ( (JP:4883) ) has provided an update.
Modalis Therapeutics reported no operating revenue for the fiscal year ended December 31, 2025, and widened its consolidated loss, with operating income at a loss of ¥2,211 million and profit attributable to owners of parent at a loss of ¥2,152 million. Total assets fell to ¥2,964 million from ¥3,691 million, equity declined, and cash and cash equivalents decreased to ¥2,812 million as operating cash outflows grew, although financing activities partially offset this.
The company maintained a no-dividend policy for 2024 and 2025 and forecasts no dividend for 2026, underscoring its focus on reinvesting capital into operations. Modalis did not provide earnings forecasts for fiscal 2026, citing difficulty in making reasonable estimates, which highlights the uncertainty typical of early-stage biotech firms and leaves investors with limited visibility on the timing of future revenue or profitability.
The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a Tokyo Stock Exchange–listed biotechnology company focused on developing genetic medicine therapies. Operating under Japanese GAAP, the company is in a pre-revenue stage and is investing in research and development to advance its pipeline, funded primarily through equity financing rather than operating cash flows.
Average Trading Volume: 837,280
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.99B
For an in-depth examination of 4883 stock, go to TipRanks’ Overview page.